GaPP2 In 'GaPP2' Birmingham Clinical Trials Unit (BCTU)GaPP2About the GaPP2 trialFor investigatorsFor trial participantsPublicationsNews and eventsContact us A multi-centre randomised controlled trial of the efficacy and mechanism of action of gabapentin for the management of chronic pelvic pain in women THE MAIN TRIAL FEATURES: A randomised controlled trial. Funded by the National Institute for Health Research (NIHR) Efficacy and Mechanism Evaluation (EME) program Run by Prof Andrew Horne (Chief Investigator). Birmingham Clinical Trials Unit at the University of Birmingham will be overseeing the administrative side of the Trial. It is hoped that 300 women with a history of pelvic pain in whom a laparoscopy reveals no obvious pelvic pathology will be recruited Participating women will be randomly allocated either Gabapentin or placebo and 50 women in Scotland will be will be recruited to an fMRI sub-study The primary outcome is dual measures of worst and average pelvic pain scores assessed by a numerical rating scale (NRS) during the final 4 weeks of treatment (weeks 13-16 post-randomisation). For the latest Patient Information Leaflet click here Browser does not support script. Browser does not support script.